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Hepatitis E, France 
To the Editor: Hepatitis E virus
(HEV) is a leading cause of acute and
fulminant hepatitis in developing
countries (1). In industrialized coun-
tries, HEV seroprevalence rates of
0.4%–3% are common, and evidence
is mounting that autochthonous trans-
mission might account for a substan-
tial proportion of infections (1–3).
Whereas fecal-oral HEV transmission
is preponderant in developing coun-
tries, other routes have been demon-
strated in industrialized countries,
among them consumption of pork or
boar meat (1,4). Parenteral transmis-
sion was first suggested but not
demonstrated (5,6). Because viruses
cannot be fully inactivated in blood
products, HEV recently emerged as a
transfusion-transmitted pathogen,
with 6 reported cases, including 3 in
which comparative analysis of HEV
sequences from blood donor and
recipient was performed (7). We
describe what is, to our knowledge,
the first case in France and the first
case worldwide involving a child as
blood recipient.
A 7-year-old boy was examined
in June 2006; he had erythematous-
papulous skin and an increased level
of alanine aminotransferase (ALT, 796
IU/L) of 1 week’s duration. From
October 2005 to May 2006, he had
received several courses of combined
chemotherapy for a rhabdoid tumor in
his kidney. Therapy included carbo-
platin, cyclophosphamide, etoposide,
adriamycin, and vincristine, and,
because of the chemotherapy’s hema-
totoxicity, the patient required 22
transfusions of concentrated erythro-
cytes or platelets. Peak levels of ALT
and bilirubin were reached 4 weeks
after onset of hepatitis (2,001 IU/L and
49 µmol/L, respectively), and ALT
levels returned to normal range (8–45
IU/L) 6 weeks later. During a follow-
up examination, the boy’s prothrom-
bin index remained >80%, and clinical
signs mostly consisted of clinical jaun-
dice. HEV diagnosis was established
by detection in serum of HEV antibod-
ies (EIAgen Kits, Adaltis Develop-
ment Inc., Laval, Quebec, Canada)
and HEV RNA with in-house assays.
Other infectious or noninfectious
causes of acute hepatitis were exclud-
ed. HEV immunoglobulin M (IgM)
was weakly positive in June 2006
(optical density ratio = 1.6), then
strongly positive the next month (ratio
= 10.8); IgG remained negative. HEV
RNA was detected from serum sam-
ples collected in June 2006 by an in-
house real-time PCR that targeted the
open reading frame 2 region of the
HEV genome. Sequences of primers/
probe are as follows: HevMrsRT
fwd: 5′-AATTRATTTCGTCGGCY
GG-3′; HevMrsRTRev: 5′- ACW
G T C G G C T C G C C AT T G - 3 ′ ;
HevMrsFam: 5′-FAM-ACTCYCGC
CASGTYGTCTCA-TAMRA-3′.
Serum samples taken from 12 U
of blood products that the child
received during the 3-month period
before onset of hepatitis were tested
for HEV RNA; 1 sample was positive.
Concentrated erythrocytes (310 mL)
from this positive blood donation
were transfused to the child in May
2006, 4 weeks after collection and 6
weeks before acute hepatitis devel-
oped. HEV IgG and IgM antibodies
were not detected in the blood dona-
tion, which indicates that the blood
donation occurred during the pro-
dromic phase of HEV disease. HEV
nucleotide sequences from the blood
donor and recipient were identical.
Phylogenetic analysis showed that
they clustered together and were
closely related to genotype 3f, which
is prevalent in Europe (Figure [8]). 
The blood donor was a 24-year-
old man. He did not travel outside
metropolitan France for 8 months
before donating blood. Anti-HEV IgG
seroconversion was observed on a
serum sample collected 24 weeks
after blood donation, whereas anti-
HEV IgM and serum HEV RNA test-
ed negative. ALT levels were within
normal values at the time of blood
donation and 24 weeks later. No clin-
ical signs were reported at any time.
No other recipient received blood
products from this donor.
Our data show that HEV was
transmitted from 1 blood donor to the
recipient child. On the basis of retro-
spective HEV RNA detection, 6 other
transfusion-transmitted HEV infec-
tions, all involving adult blood recipi-
ents, have occurred in HEV-hyperen-
demic and industrialized countries
(7). Transfusion-transmitted HEV
strains belonged to different geno-
types/subtypes that corresponded to
those found in the same geographic
areas (Figure).
In France, neither HEV antibod-
ies nor HEV RNA are systematically
tested in blood donors, and blood
donations currently are not tested for
ALT. In the absence of systematic
HEV RNA testing, HEV diagnosis in
blood donations may be hampered by
HEV viremia before clinical onset and
anti-HEV seroconversion, the possi-
ble short persistence or absence of
HEV antibodies, and the high fre-
quency of subclinical infections
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(1,2,5). On the basis of these data,
improved knowledge of HEV epi-
demiology in the general population
and in blood donors is needed in
industrialized countries to guide HEV
screening policy for blood products. 
Another concern of transfusion-
transmitted HEV infections is the
potential severity of acute hepatitis E.
Previously reported cases of contami-
nation through transfusion and our
case showed spontaneous recovery.
However, although typically self-lim-
ited, hepatitis E is potentially life-
threatening with mortality rates of
0.2%–4%, reaching 20% in pregnant
women (1). Fatal outcome has also
been described in children (9). In
summary, HEV-contaminated blood
donations are a challenge for diagno-
sis and virus safety of transfusion,
including in industrialized countries.
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Figure. Outline of phylogenetic tree constructed by the neighbor-joining method based on
partial nucleotide sequences of the open reading frame (ORF) 2 region of hepatitis E virus
(HEV) genome obtained from the blood donor and blood recipient, with sequences of
other local HEV strains previously identified and published HEV sequences (8). Bootstrap
values are indicated when >50% as a percentage obtained from 100 resamplings of the
data. Black squares indicate HEV sequences from the blood donor and recipient
(GenBank accession nos. EF028801 and EF028802); white squares indicate HEV
sequences from other individuals with hepatitis E living in Marseille and environs; white tri-
angles indicate HEV sequences from the United Kingdom (3) that have an 80%–100%
homology at the nucleotide level with those obtained by Boxall et al. (7). See online fig-
ure, available at http://www.cdc.gov/content/EID/13/4/648-G.htm, for complete phylo-
genetic tree and details of methods and sequences.
